Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011 (2011), Article ID 970804, 9 pages
http://dx.doi.org/10.1155/2011/970804
Research Article

A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk

1Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
2Department of Pathology and Laboratory Medicine, The Mount Sinai Hospital, Toronto, ON, Canada M5G 1X5
3Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227, USA
4Department of Pathology and Laboratory Medicine, Weill-Cornell Medical Center, New York, NY 10065, USA
5Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA

Received 11 March 2011; Revised 11 April 2011; Accepted 3 May 2011

Academic Editor: J. F. Simpson

Copyright © 2011 Geoffrey C. Kabat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Vogelstein and K. W. Kinzler, “The multistep nature of cancer,” Trends in Genetics, vol. 9, no. 4, pp. 138–141, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. E. R. Fearon and B. Vogelstein, “A genetic model for colorectal tumorigenesis,” Cell, vol. 61, no. 5, pp. 759–767, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. F. R. Miller, H. D. Soule, L. Tait et al., “Xenograft model of progressive human proliferative breast disease,” Journal of the National Cancer Institute, vol. 85, no. 21, pp. 1725–1732, 1993. View at Google Scholar · View at Scopus
  4. H. Tsuda, “Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression,” Breast Cancer, vol. 16, no. 3, pp. 186–201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Done, S. Eskandarian, S. Bull, M. Redston, and I. L. Andrulis, “P53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast,” Journal of the National Cancer Institute, vol. 93, no. 9, pp. 700–704, 2001. View at Google Scholar · View at Scopus
  6. M. Hollstein, D. Sidransky, B. Vogelstein, and C. C. Harris, “p53 Mutations in human cancers,” Science, vol. 253, no. 5015, pp. 49–53, 1991. View at Google Scholar · View at Scopus
  7. R. J. Osborne, G. R. Merlo, T. Mitsudomi et al., “Mutations in the p53 gene in primary human breast cancers,” Cancer Research, vol. 51, no. 22, pp. 6194–6198, 1991. View at Google Scholar · View at Scopus
  8. H. Tsuda, K. Iwaya, T. Fukutomi, and S. Hirohashi, “P53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade,” Japanese Journal of Cancer Research, vol. 84, no. 4, pp. 394–401, 1993. View at Google Scholar · View at Scopus
  9. J. Bergh, T. Norberg, S. Sjogren, A. Lindgren, and L. Holmberg, “Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy,” Nature Medicine, vol. 1, no. 10, pp. 1029–1034, 1995. View at Google Scholar · View at Scopus
  10. M. Olivier, A. Langerød, P. Carrieri et al., “The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer,” Clinical Cancer Research, vol. 12, no. 4, pp. 1157–1167, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Ozcelik, D. Pinnaduwage, S. B. Bull, and I. L. Andrulis, “Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer,” Breast Cancer Research and Treatment, vol. 105, no. 3, pp. 255–265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Sjögren, M. Inganäs, T. Norberg et al., “The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry,” Journal of the National Cancer Institute, vol. 88, no. 3-4, pp. 173–182, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. D. W. Visscher, F. H. Sarkar, R. K. Shimoyama, and J. D. Crissman, “Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma,” Diagnostic Molecular Pathology, vol. 5, no. 3, pp. 187–193, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Alsner, V. Jensen, M. Kyndi et al., “A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients,” Acta Oncologica, vol. 47, no. 4, pp. 600–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Tripathy and C Benz, “Activated oncogenes and putative tumour suppressor genes involved in human breast cancer,” in Oncogenes and Tumor Suppressor Genes in Human Malignancies, pp. 15–60, Kluwer Academic Publishers, Norwell, Mass, USA, 1993. View at Google Scholar
  16. M. J. van de Vijver, “Molecular genetic changes in human breast cancer,” in Advances in Cancer Research, G. F. Vande Woude, Ed., vol. 61, pp. 25–56, Academic Press, New York, NY, USA, 1993. View at Google Scholar
  17. A. Levine, J. Momand, and C. A. Finlay, “The p53 tumour suppressor gene,” Nature, vol. 351, no. 6326, pp. 453–456, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Hartmann, H. Błaszyk, J. S. Kovach, and S. S. Sommer, “The molecular epidemiology of P53 gene mutations in human breast cancer,” Trends in Genetics, vol. 13, no. 1, pp. 27–33, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Done, N. C. R. Arneson, H. Özçelik, M. Redston, and I. L. Andrulis, “p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias,” Cancer Research, vol. 58, no. 4, pp. 785–789, 1998. View at Google Scholar · View at Scopus
  20. F. P. O'Malley, C. L. Vnencak-Jones, W. D. Dupont, F. Parl, S. Manning, and D. L. Page, “p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data,” Laboratory Investigation, vol. 71, no. 1, pp. 67–72, 1994. View at Google Scholar · View at Scopus
  21. P. B. Rajan, D. J. Scott, R. H. Perry, and C. D. M. Griffith, “p53 protein expression in ductal carcinoma in situ (DCIS) of the breast,” Breast Cancer Research and Treatment, vol. 42, no. 3, pp. 283–290, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Bartek, J. Bartkova, B. Vojtesek et al., “Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro,” International Journal of Cancer, vol. 46, no. 5, pp. 839–844, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. D. N. Poller, E. C. Roberts, J. A. Bell, C. W. Elston, R. W. Blamey, and I. O. Ellis, “p53 Protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein,” Human Pathology, vol. 24, no. 5, pp. 463–468, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. F. C. Schmitt, C. Leal, and C. Lopes, “p53 Protein expression and nuclear DNA content in breast intraductal proliferations,” Journal of Pathology, vol. 176, no. 3, pp. 233–241, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Younes, R. M. Lebovitz, K. E. Bommer et al., “p53 Accumulation in benign breast biopsy specimens,” Human Pathology, vol. 26, no. 2, pp. 155–158, 1995. View at Google Scholar · View at Scopus
  26. B. W. Lisboa, S. Vogtländer, T. Gilster, L. Riethdorf, K. Milde-Langosch, and T. Löning, “Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer,” Virchows Archive, vol. 431, no. 6, pp. 375–381, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Millikan, B. Hulka, A. Thor et al., “p53 Mutations in benign breast tissue,” Journal of Clinical Oncology, vol. 13, no. 9, pp. 2293–2300, 1995. View at Google Scholar · View at Scopus
  28. R. A. Kandel, S. Q. Li, H. Ozcelik, and T. E. Rohan, “p53 protein accumulation and mutations in normal and benign breast tissue,” International Journal of Cancer, vol. 87, no. 1, pp. 73–78, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. C. J. Fabian, S. Kamel, C. Zalles, and B. F. Kimler, “Identification of a chemoprevention cohort from a population of women at high risk for breast cancer,” Journal of Cellular Biochemistry, vol. 63, no. 25, pp. 112–122, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. T. E. Rohan, W. Hartwick, A. B. Miller, and R. A. Kandel, “Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk,” Journal of the National Cancer Institute, vol. 90, no. 17, pp. 1262–1269, 1998. View at Google Scholar · View at Scopus
  31. T. E. Rohan, S. Q. Li, R. Hartwick, and R. A. Kandel, “p53 alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 7, pp. 1316–1323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. G. C. Kabat, J. G. Jones, N. Olson et al., “A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer,” Cancer Causes and Control, vol. 21, pp. 821–828, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. G. C. Kabat, J. G. Jones, N. Olson et al., “Risk factors for breast cancer in women biopsied for benign breast disease: a nested case-control study,” Cancer Epidemiology, vol. 34, no. 1, pp. 34–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. D. L. Page and T. J. Anderson, Diagnostic Histopathology of the Breast, Churchill Livingstone, New York, NY, USA, 1987.
  35. N. E. Breslow and N. E. Day, Statistical Methods in Cancer Research, vol. 1, no. 32, IARC Scientific Publications, Lyon, France, 1980.
  36. L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark, “Reporting recommendations for tumor MARKer prognostic studies (REMARK),” Nature Clinical Practice Oncology, vol. 2, no. 8, pp. 416–422, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Soussi, “p53 alterations in human cancer: more questions than answers,” Oncogene, vol. 26, no. 15, pp. 2145–2156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Soussi and K. G. Wiman, “Shaping genetic alterations in human cancer: the p53 mutation paradigm,” Cancer Cell, vol. 12, no. 4, pp. 303–312, 2007. View at Publisher · View at Google Scholar · View at Scopus